|1.||Fisher, Abraham: 6 articles (07/2008 - 08/2002)|
|2.||Messer, William S: 5 articles (03/2014 - 04/2002)|
|3.||Fisher, A: 4 articles (01/2002 - 01/2000)|
|4.||Shannon, H E: 4 articles (09/2001 - 09/2000)|
|5.||Nathanson, Neil M: 3 articles (02/2015 - 04/2003)|
|6.||Felder, Christian C: 3 articles (07/2014 - 04/2003)|
|7.||Lu, Yang: 3 articles (08/2013 - 07/2003)|
|8.||Chen, Hong-Zhuan: 3 articles (08/2013 - 07/2003)|
|9.||Fiszman, Gabriel L: 3 articles (02/2013 - 07/2007)|
|10.||Jones, Carrie K: 3 articles (01/2012 - 03/2005)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2002 - "Impact of muscarinic agonists for successful therapy of Alzheimer's disease."
03/01/2000 - "Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors."
08/01/2002 - "Recent studies suggesting a role for muscarinic agonists in regulating the production of A beta raise the possibility that selective M1 agonists could be useful in treating not only the symptoms, but also the underlying cause(s) of Alzheimer's disease. "
10/09/1990 - "Although a number of muscarinic agonists have been used in clinical trials for Alzheimer's Disease, many of these compounds are low in potency and have only limited intrinsic efficacy. "
10/01/1984 - "After toxicity studies in dogs, a preliminary feasibility trial of the continuous intracranial infusion of a muscarinic agonist was begun in four patients with biopsy-documented Alzheimer's disease. "
|2.||Schizophrenia (Dementia Praecox)
03/01/2005 - "Collectively, the present findings demonstrate that a functional interaction occurs between the muscarinic cholinergic and dopaminergic systems in modulating PPI and that muscarinic cholinergic agonists may be effective in the treatment of the PPI and other cognitive impairments observed in schizophrenia."
07/01/2014 - "The M(4) receptor is a compelling therapeutic target, as this receptor modulates neural circuits dysregulated in schizophrenia, and there is clinical evidence that muscarinic agonists possess both antipsychotic and procognitive efficacy. "
01/01/2012 - "Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions."
01/01/2009 - "Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia."
11/01/2008 - "Muscarinic agonists for the treatment of cognition in schizophrenia."
01/01/2012 - "Extensive preclinical and clinical validation of these mechanisms points to the development of selective muscarinic agonists as one of the most exciting and promising avenues toward novel pain medications."
09/01/2007 - "Here, we have investigated the in vitro pharmacology of a muscarinic agonist, (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983), and we demonstrated its activity in several models of pain. "
09/01/2007 - "Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain."
09/01/2001 - "It is well established that muscarinic cholinergic agonists produce antinociceptive effects in a number of acute pain models. "
09/01/2007 - "The data presented herein suggest that muscarinic agonists, such as WAY-132983, may have a broad therapeutic efficacy for the treatment of pain."
|4.||Nervous System Diseases (Neurological Disorders)
09/25/2003 - "Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders."
12/20/2001 - "Selective muscarinic agonists could be useful in the treatment of neurological disorders such as Alzheimer's disease, schizophrenia, and chronic pain. "
01/01/2004 - "Bivalent ligands represent an important starting point for the development of selective muscarinic agonists with potential utility in treating a variety of neurological disorders, including Alzheimer's disease and schizophrenia. "
09/25/2003 - "Muscarinic agonists might be useful in the treatment of neurological disorders, including Alzheimer's disease, schizophrenia, chronic pain, and drug abuse. "
01/01/2012 - "Conversely, both direct-acting muscarinic receptor agonists and indirect-acting muscarinic cholinergic agonists, such as acetylcholinesterase inhibitors, have shown cognition-enhancing properties, including improvements in normal cognitive function, reversal of cognitive deficits induced by muscarinic receptor antagonists, and attenuation of cognitive deficits in psychiatric and neurological disorders, such as Alzheimer's disease and schizophrenia. "
|5.||Memory Disorders (Memory Loss)
12/01/2006 - "Thus, this study demonstrates the potential of cholinergic muscarinic agonists and the involvement of both cholinergic and noradrenergic systems in the reversal of stress-induced learning and memory deficits."
04/01/2002 - "Thus far, the clinical utility of muscarinic agonists remains unproven, yet recent studies suggest that muscarinic agonists might be useful in treating not only memory deficits, but also psychiatric disturbances and some of the underlying causes of Alzheimer's disease, such as the deposition of Abeta. "
03/01/2000 - "Cholinergic neurons degenerate in Alzheimer's disease, resulting in cognitive impairments and memory deficits, and drug development efforts have focused on selective M1 muscarinic agonists. "
06/14/1991 - "These results suggest that certain muscarinic agonists may be useful in reducing the memory deficits of patients with Alzheimer's disease."
09/20/1991 - "In contrast, intraperitoneal doses (0.032-3.2 mg/kg) of pilocarpine, a muscarinic agonist, showed a significant improvement of both types of memory deficit with bell shaped dose-response curves. "
|4.||2- ethyl- 8- methyl- 2,8- diazaspiro(4,5)decane- 1,3- dione (RS 86)
|6.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|1.||Drug Therapy (Chemotherapy)